Na+偶联单羧酸转运蛋白及其在药物转运中的作用

中国临床药理学与治疗学 ›› 2009, Vol. 14 ›› Issue (1): 103-109.

Na⁺偶联单羧酸转运蛋白及其在药物转运中的作用

许秋霞, 王寅, 马丽焱

中国医学科学院中国协和医科大学药用植物研究所, 北京 100193

收稿日期:2008-10-10 修回日期:2008-11-11 出版日期:2009-01-26 发布日期:2020-10-27
通讯作者: 马丽焱,女, 博士, 硕士研究生导师, 研究员, 研究方向:药代动力学。Tel:010-62899717-869 E-mail: lyma@implad.ac.cn
作者简介:许秋霞, 女, 硕士研究生, 研究方向:药代动力学。
基金资助:
国家中医药管理局留学回国人员择优项目(国中医药函[2006] 51号)

Sodium-coupled monocarboxylate transporters and their actions in drug delivery

XU Qiu-xia, WANG Yin, MA Li-yan

Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences &Peking Union Medical College,Beijing 100193, China

Received:2008-10-10 Revised:2008-11-11 Online:2009-01-26 Published:2020-10-27

摘要/Abstract

摘要： Na⁺偶联单羧酸转运蛋白(sodium-coupled monocarboxylate transporter, SMCTs)包括两种亚型: SMCT1 和SMCT2 。两者的底物特异性相似, 但 SMCT1 对底物的亲和力比SMCT2 高。在机体中,SMCT1 和SMCT2 表达于肠道、肾脏和视网膜并通过协同作用促进相应组织对单羧酸的转运, 以维持机体的生理功能。本文从生物学特征、底物与抑制剂、组织分布与生理功能及其在药物转运中的作用等方面对SMCT1 和SMCT2 进行综述。

关键词: Na⁺偶联单羧酸转运蛋白, 生物学特征, 组织分布, 生理功能, 药物转运

Abstract: Sodium-coupled monocarboxylate transporters contain two subtypes:SMCT1 and SMCT2. Both of them have similar substrate specificity, but SMCT1 has higher affinity for substrate than SMCT2.SMCT1 and SMCT2 are expressed in intestine, kidney and retina.They maintain physiological function of the tissues by transporting monocarboxylate cooperately.In this paper, the biological characteristics, substrates and inhibitors, tissue distribution and physiological function, as well as actions in drug delivery of SMCT1 and SMCT2 are reviewed.

Key words: sodium-coupled monocarboxylate transporter, biological characteristics, tissue distribution, physiological function, drug delivery

中图分类号:

R969.1

许秋霞, 王寅, 马丽焱. Na⁺偶联单羧酸转运蛋白及其在药物转运中的作用[J]. 中国临床药理学与治疗学, 2009, 14(1): 103-109.

XU Qiu-xia, WANG Yin, MA Li-yan. Sodium-coupled monocarboxylate transporters and their actions in drug delivery[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(1): 103-109.

参考文献

[1] Halestrap AP, Meredith D.The SLC16 gene family-from monocarboxylate transporters (MCTs) to aromatic amino acid transporters and beyond[J]. Pflugers Arch, 2004,447(5):619-628.
[2] 曾军英, 韩雪峰, 谭支良.单羧酸转运蛋白家族及其生物学功能[J]. 生命的化学, 2008, 28(4):404-407.
[3] Coady M, Chang MH, Charron FM, et al. The human tumour suppressor gene SLC5A8 expresses a Na+-monocarboxylate cotransporter[J]. J Phy siol, 2004, 557(3):719-731.
[4] Gopal E, Umapahy NS, Martin PM, et al. Cloning and functional characterization of human SMCT2 (SLC5A12) and expression pattern of the transporter in kidney[J]. Biochim Biophysica Acta, 2007, 1768(11):2690-2697.
[5] Gopal E, Fei YJ, Sugawara M, et al. Expression of slc5a8 in kidney and its role in Na+-coupled transporter of lactate[J]. J Biol Chem, 2004, 279(43):44522-44532.
[6] Coady MJ, Wallendorff B, Bourgeois F, et al. Establishing a definitive stoichiometry for the Na+ monocarboxylate cotransporter SMCT1[J]. Biophy J, 2007, 93(7):2325-2331.
[7] Ganapathy V, Thangaraju M, Gopal E, et al. Sodiumcoupled monocarboxy late transporters in normal tissues and in cancer[J]. AAPS, 2008, 10(1):193-199.
[8] Rodriguez AM, Perron B, Lacroix L, et al. Identification and characterization of a putative human iodide transporter located at the apical membrane of thyrocytes[J]. J Clin EndocrinolMetab, 2002, 87(7):3500-3503.
[9] Paroder V, Spencer SR, Paroder M, et al. Na+ monocarboxylate transport (SMCT)protein expression correlates with survival in colon cancer:molecular characterization of SMCT[J]. PNAS, 2006, 103(19):7270-7275.
[10] Srinivas SR, Gopal E, Zhuang L, et al. Cloning and functional identification of slc5a12 as a sodium-coupled low- affinity transporter for monocarboxylates (SMCT2)[J]. Biochem J, 2005, 392(Pt 3):655-664.
[11] Thangaraju M, Cresci G, Itagaki S, et al. Sodium-coupled transport of the short chain fatty acid butyrate by SLC5A8 and its relevance to colon cancer[J]. J Gastrointest Surg, 2008, 12(10):1773-1781.
[12] Miyauchi S, Gopal E, Fei YJ, et al. Functional identification of SLC5A8, a tumor suppressor down-regulated in colon cancer, as a Na⁺-coupled transporter for shortchain fatty acids[J]. J Biol Chem, 2004, 279(14):13293-13296.
[13] Gopal E, Miyauchi S, Martin PM, et al. Transport of nicotinate and structurally related compounds by human SMCT1 (SLC5A8) and its relevance to drug transport in the mammalian intestinal tract[J]. Pharm Res, 2007, 24(3):575-584.
[14 ] Martin PM, Gopal E, Ananth S, et al. Identity of SMCT1 (SLC5A8) as a neuron-specific Na+-coupled transporter for active uptake of L-lactate and ketone bodies in the brain[J]. J Neurochem, 2006, 98(1):279-288.
[15] Ganapathy V, Gopal E, Miyauchi S, et al. Biological functions of SLC5A8, a candidate tumour suppressor[J]. Biochem Soc Trans, 2005, 33(Pt 1):237-240.
[16] Takebe K, Nio J, Morimatsu M, et al. Histochemical demonstration of a Na+-coupled transporter for short-chain fatty acids(slc5a8) in the intestine and kidney of the mouse[J]. Bio Res, 2005, 26(5):213-221.
[17] Gopal E, Fei YJ, Miyauchi S, et al. Sodium-coupled and electrogenic transport of B-complex vitamin nicotinic acid by slc5a8, a member of the Na glucose co-transporter gene family[J]. Biochem J, 2005, 388(Pt 1):309-316.
[18] Martin PM, Dun Y, Mysona B, et al. Expression of the sodium-coupled monocarboxylate transporters SMCT1 (SLC5A8)and SMCT2 (SLC5A12)in retina[J]. IOVS,2007, 48(7):3356-3363.
[19] Gupta N, Martin PM, Prasad PD, et al. SLC5A8 (SMCT1)-mediated transport of butyrate forms the basis for the tumor suppressive function of the transporter[J]. Life Sci, 2006, 78(21):2419-2425.
[20] Cuff MA, Shirazi-Beechey SP.The importance of butyrate transport to the regulation of gene expression in the colonic epithelium[J]. Biochem Soc Trans, 2004, 32(Pt 6): 1100-1102.
[21] Thangaraju M, Ananth S, Martin PM, et al. c ebpδNull mouse as a model for the double knock-out of slc5a8 and slc5a12 in kidney[J]. J Biol Chem, 2006, 281(37):26769-26773.
[22] Laffel L.Ketone bodies:a review of physiology, pathophy siology and application of monitoring to diabetes[J]. Diabetes Metab Res Rev, 1999, 15(6):412-426.
[23] Allgayer H.mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease[J]. Aliment Pharmacol Ther, 2003, 18(2):10-14.
[24] MacDermott RP.Progress in understanding the mechanisms of action of 5-aminosalicylic acid[J]. Am J Gastroenterol,2000, 95(12):3343-3345.
[25] Gisbert JP, Gomollón F, Maté J, et al. Role of 5-aminosalicylic acid (5-ASA)in treatment of inflammatory bowel disease:a systematic review[J]. Dig Dis Sci, 2002, 47(3):471-488.
[26] Itagaki S, Gopal E, Zhuang L, et al. Interaction of ibuprofen and other structurally related NSAIDs with the sodium-coupled monocarboxylate transporter SMCT1(SLC5A8)[J]. Pharm Res, 2006, 23(6):1209-1216.

[1]	郭璐, 钟振东, 韩奕岑, 石毅, 杨勇, 边原, 刘晓姝, 张静, 郎琴, 钟甜. 不同给药方式在大鼠内对利巴韦林的药代动力学和组织分布的影响[J]. 中国临床药理学与治疗学, 2022, 27(1): 25-32.
[2]	杨欢, 石玉红, 冉海凤, 陈怡瑾, 徐晓玉. 促红细胞生成素的生理功能及生成来源[J]. 中国临床药理学与治疗学, 2021, 26(4): 434-443.
[3]	钟凯龙, 王永胜, 陈方, 叶岩荣. 基于血脑屏障转运体的中枢神经系统疾病治疗策略探讨与展望#br#[J]. 中国临床药理学与治疗学, 2020, 25(8): 953-960.
[4]	陈爱瑛, 程敏, 繆云萍, 叶小弟, 田雪君, 郑高利. 舒尼替尼药代动力学和脑肾组织分布特征[J]. 中国临床药理学与治疗学, 2020, 25(10): 1105-1110.
[5]	刘妍, 刘嘉莉, 贾元威, 周芳, 王广基, 张经纬. 抗肿瘤药物的瘤内转运评价研究进展[J]. 中国临床药理学与治疗学, 2020, 25(10): 1151-1159.
[6]	邢晗，宁晨，孔德璇，蔡卉，周时雨，任畅，孔颖，程钰洁，陈西敬. 高抗肿瘤活性汉黄芩素衍生物GL-V9在大鼠体内的组织分布和排泄研究[J]. 中国临床药理学与治疗学, 2019, 24(8): 889-895.
[7]	陈曜曜，史道华，刘光华，牛培广，刘柏晨. OCT2、MDR1基因多态性与婴幼儿万古霉素血药浓度及临床疗效的相关性研究[J]. 中国临床药理学与治疗学, 2018, 23(2): 154-158.
[8]	袁雅文，李岩，杨劲. LC-MS/MS法测定对氨基水杨酸浓度及在大鼠组织分布研究中的应用[J]. 中国临床药理学与治疗学, 2017, 22(3): 272-280.
[9]	姚天怡, 尹少平, 刘雯, 赵炎磊, 王广基, 李娟. 紫杉醇聚合物胶束的组织分布和生物学评价[J]. 中国临床药理学与治疗学, 2017, 22(11): 1207-1214.
[10]	谢偲, 岳丽杰. 基因多态性对巯嘌呤类药物作用影响的研究进展[J]. 中国临床药理学与治疗学, 2014, 19(7): 818-823.
[11]	唐志华, 王玮, 丁洁卫. 雾化吸入氨茶碱在犬体内的组织分布[J]. 中国临床药理学与治疗学, 2014, 19(2): 150-155.
[12]	李荣辉, 黄美玲, 谭鸿毅, 裴奇, 项玉霞, 阳国平. 非酒精性脂肪肝对药动学影响研究进展[J]. 中国临床药理学与治疗学, 2013, 18(9): 1065-1075.
[13]	高利臣, 张伟, 刘昭前, 范岚, 周宏灏. 药物代谢相关基因介导的中草药药物相互作用研究[J]. 中国临床药理学与治疗学, 2012, 17(3): 346-351.
[14]	彭丹, 夏春华, 熊玉卿. 有机阴离子转运多肽1A2对药物转运的影响[J]. 中国临床药理学与治疗学, 2010, 15(4): 464-469.
[15]	王磊, 李宁, 陈西敬. 转运体在药物排泄中的作用及在新药研发中的意义[J]. 中国临床药理学与治疗学, 2009, 14(4): 448-454.